Therapeutic answer in patients who suffers from polycystic ovary syndrome

Authors

  • Alicia González Reigada
  • Félix González González
  • Diosdado Coll Bujardón
  • Niurka Figueredo Trimiño
  • Ubilkis Ramos Agüero
  • Ignacio Cabrera Figueredo

Abstract

Background: polycystic ovary syndrome is an heterogeneous disorder; it has been recognized as the main cause of infertility on women during reproductive ages.
Objective: to determine the therapeutic answer on patients who suffers from polycystic ovary syndrome in Camaguey during January 2013 to January 2015.
Methods: an observational descriptive and longitudinal study was carried out. The universe was sample by all patients who were diagnosed with polycystic ovary syndrome. The data were processed by descriptive statistics.
Results: 66,97 % of patients answered to the treatment and 70,00 % of patients who had normoandrogenic type answered correctly too. After the treatment 55,50 % of patients continuous with ovary volume higher than 13 mL.
Conclusions: the most important variation were to reduce blood levels of testosterone and to increase blood levels of progesterone. The therapeutic combination more used was hygienic-dietetic changes plus metformina.
DeCS: POLYCYSTIC OVARY SYNDROME/therapy; PROGESTERONE/therapeutic use; TREATMENT OUTCOME; INFERTILITY, FEMALE; EPIDEMIOLOGY, DESCRIPTIVE.

Downloads

Download data is not yet available.

References

1. Jara Díaz JF de la, Ortega González C. Síndrome de ovario poliquístico. Rev Mex Med Reproduc [Internet]. 2011 [citado 5 May 2013];4(2):[aprox. 7 p.]. Disponible en: http://www.medigraphic.com/pdfs/reproduccion/mr-2011/mr112b.pdf

2. Petríková J, Lazúrová I, Shoenfeld Y. Polycystic ovary syndrome and Autoimmunity. New York: Raven Press; 1995.

3. Diamanti Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endoc Rev [Internet]. 2012 Dec [citado 2013 May 5];33(6):[about 4 p.]. Available from: http://press.endocrine.org/doi/pdf/10.1210/er.2011-1034

4. Laven J, Imani B, Eijkemans MJ, Fauser BC. New Approach to Polycystic Ovary Syndrome and Other Forms of Anovulatory Infertility. Obstet Gynecol Surv. 2002 Nov;57(11):755-67.

5. Bentley Lewis R, Seely E, Dunaif A. Ovarian Hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am [Internet]. 2011 Jun [citado 2013 May 5];40(2):[about 11 p.]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253555/.

6. Florez JC. Genetic Susceptibility for Polycystic Ovary Syndrome on Chromosome 19: advances in the genetic dissection of complex reproductive traits. J Clin Endocrinol Metab [Internet] 2005 Dec [citado 2013 May 5];90(12):[about 12 p.]. Available from: http://press.endocrine.org/doi/10.1210/jc.2005-2204?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

7. Monteagudo Peña G. Diagnóstico y tratamiento del síndrome de ovarios poliquísticos. La Habana: Curso de actualización de Endocrinología; 2011.

8. López Iñiguez A. Síndrome de Ovário Poliquístico. Rev Méd [Internet]. 2010 [citado 5 May 2013];6(1):[aprox. 7 p.]. Disponible en: http://www.medigraphic.com/pdfs/revmed/md-2010/md106d.pdf

9. Checa Vizcaíno MA. Síndrome del ovario poliquístico. Médica Panamericana. 2005;24(2):182.

10. Sir-Petermann T. Síndrome de ovario poliquístico: la importancia de establecer su diagnóstico. Rev Méd Chile. 2011;129(7):42-53.

11. Acosta Cedeño A, Monteagudo Peña G, Menocal Alayón A. Patrón hormonal de mujeres con diagnóstico clínico y ecográfico del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol [Internet]. Ago 2004 [citado 2 Feb 2015];5(2):[aprox. 6 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532004000200003&lng=es

12. Espinoza Alvarado C, Matute García NC, Ochoa Rueda S, López Lutz E. Caracterización clínica de pacientes con Síndrome de Ovario poliquístico. Rev Méd Hondur [Internet]. 2011 [citado 2 Feb 2015];79(3):[aprox. 5 p.]. Disponible en: http://www.bvs.hn/RMH/pdf/2011/pdf/Vol79-3-2011-5.pdf

13. Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013 Aug;78(8):773-6.

14. Guo M, Chen ZJ, Eijkemans MJ, Goverde AJ, Fauser BC, Macklon NS.Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhea. Hum Reprod [Internet]. 2012 May [citado 2015 Feb 2];27(5):[about 10 p.]. Available from: http://humrep.oxfordjournals.org/content/27/5/1481.long

15. Fux C. Síndrome de ovario poliquístico: revisión de su fisiopatogenia. Rev Fac Cienc Méd. 2013;70(1):27-30.

16. Rodrigo Carvajal G, Cristian Herrera G, Arnaldo Porcile J. Espectro fenotípico del Síndrome de Ovario Poliquístico. Rev chilena obstetr ginecol. 2010;75(2):124-32.

17. Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010 May;139(5):825-33.

18. Bungum L, Franssohn F, Bungum M, Humaidan P, Giwercman A. The circadian variation in Anti-Mullerian hormone in patients with polycystic ovary syndrome differssignificantly from normally ovulating women. PLoS One [Internet]. 2013 Sep 4 [citado 2015 Feb 2];8(9):[about 5 p.]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762839/.

19. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist [Internet]. 2011 [citado 2015 Feb 2];16(4):[about 12 p.]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228118/.

20. Azziz R, Carmina E, Dewailly D, Diamanti Kandarakis E, Escobar Morreale HF, Futterweit W, et al. Criteria for definig polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45.

21. Davis SR, Panjari M, Stanczyk FZ. DHEA replacement for postmenopausal women. J Clin Endocrinol Metab [Internet]. 2011 [citado 2015 Feb 2];96(6):[about 14 p.]. Available from: http://press.endocrine.org/doi/full/10.1210/jc.2010-2888

22. Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab [Internet]. 2014 [citado 2015 Feb 2];99(10):[about 8 p.]. Available from: http://press.endocrine.org/doi/10.1210/jc.2014-2262?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

23. Fernandes T, Costa Paiva LH, Pinto Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med [Internet]. 2014 May [citado 2015 Feb 2];11(5):[about 7 p.]. Available from: http://www.pubfacts.com/detail/24612478/Efficacy-of-vaginally-applied-estrogen-testosterone-or-polyacrylic-acid-on-sexual-function-in-postme

24. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab [Internet]. 2012 Feb [citado 2015 Feb 2];97(2):[about 12 p.]. Available from: http://press.endocrine.org/doi/10.1210/jc.2011-2134?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

25. Dipankar B, Salil Kumar M, Satinath M, Mamata P. Clinical correlation with biochemical status in polycystic ovarian syndrome. J Obstet Gynecol India [Internet]. 2005 [citado 2015 Feb 2];55(1):[about 8 p.]. Available from: http://medind.nic.in/jaq/t05/i1/jaqt05i1p67.pdf

26. Ovies Carballo G, Domínguez Alonso E, Verdeja Varela OL, Zamora Recinos H. Frecuencia y características clínicas, hormonales y ultrasonográficas sugestivas de síndrome de ovarios poliquísticos en un grupo de mujeres con síndrome metabólico. Rev Cubana Endocrinol. 2008;19(3):20-24.

27. Bonilla-Musoles F, Castillo Farfán JC, Raga F, Bonilla F, Caballero Luna O. Alta definición ecográfica en tiempo real (HDLive US) en Obstetricia y Ginecología. Rev Per Ginecol Obstet. 2013;59(1):407-13.

28. Carmina E, Campagna AM, Lobo RA. A 20-year followup of young women with polycystic ovary syndrome. Obstet Gynecol. 2012;119(2 Pt 1):263-9.

29. Cabrera Gamez M. Tratamiento con sensibilizadores de insulina en el SOP. Consenso Síndrome de Ovarios Poliquísticos. La Habana: Instituto Nacional de Endocrinología; 2015.

30. Rodríguez Flores M. Síndrome de ovario poliquístico: el enfoque del internista. Med Int Mex [Internet]. 2012 [citado 5 May 2013];28(1):[aprox. 8 p.]. Disponible en: http://www.medigraphic.com/pdfs/medintmex/mim-2012/mim121h.pdf

Downloads

Published

2017-03-27

How to Cite

1.
González Reigada A, González González F, Coll Bujardón D, Figueredo Trimiño N, Ramos Agüero U, Cabrera Figueredo I. Therapeutic answer in patients who suffers from polycystic ovary syndrome. Arch méd Camagüey [Internet]. 2017 Mar. 27 [cited 2025 Aug. 1];21(2):191-20. Available from: https://revistaamc.sld.cu/index.php/amc/article/view/4802

Issue

Vol. 21 No. 2 (2017)

Section

Original Articles

License

Copyright: Camagüey Medical Archive Magazine, offers immediately after being indexed in the SciELO Project; Open access to the full text of the articles under the principle of making available and free the research to promote the exchange of global knowledge and contribute to a greater extension, publication, evaluation and extensive use of the articles that can be used without purpose As long as reference is made to the primary source.

Conflicts of interest: authors must declare in a mandatory manner the presence or not of conflicts of interest in relation to the investigation presented.

(Download Statement of potential conflicts of interest)

The Revista Archivo Médico de Camagüey is under a License Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 International (CC BY 4.0).

This license allows others to distribute, to mix, to adjust and to build from its work, even for commercial purposes, as long as it is recognized the authorship of the original creation. This is the most helpful license offered. Recommended for maximum dissemination and use of licensed materials. The full license can be found at: https://creativecommons.org/licenses/